TW239131B - - Google Patents

Info

Publication number
TW239131B
TW239131B TW082106302A TW82106302A TW239131B TW 239131 B TW239131 B TW 239131B TW 082106302 A TW082106302 A TW 082106302A TW 82106302 A TW82106302 A TW 82106302A TW 239131 B TW239131 B TW 239131B
Authority
TW
Taiwan
Application number
TW082106302A
Other languages
Chinese (zh)
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Application granted granted Critical
Publication of TW239131B publication Critical patent/TW239131B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW082106302A 1992-08-06 1993-08-06 TW239131B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/926,795 US5310929A (en) 1992-08-06 1992-08-06 Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists

Publications (1)

Publication Number Publication Date
TW239131B true TW239131B (OSRAM) 1995-01-21

Family

ID=25453732

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082106302A TW239131B (OSRAM) 1992-08-06 1993-08-06

Country Status (18)

Country Link
US (1) US5310929A (OSRAM)
EP (1) EP0654027A1 (OSRAM)
JP (1) JP2892838B2 (OSRAM)
CN (1) CN1090275A (OSRAM)
AU (1) AU688735B2 (OSRAM)
BR (1) BR9306911A (OSRAM)
CA (1) CA2141692C (OSRAM)
FI (1) FI950485A0 (OSRAM)
HU (1) HU9500349D0 (OSRAM)
IL (1) IL106553A0 (OSRAM)
MX (1) MX9304787A (OSRAM)
NO (1) NO950404D0 (OSRAM)
PL (1) PL307309A1 (OSRAM)
SG (1) SG47108A1 (OSRAM)
SK (1) SK13195A3 (OSRAM)
TW (1) TW239131B (OSRAM)
WO (1) WO1994003435A1 (OSRAM)
ZA (1) ZA935693B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují
ATE266402T1 (de) * 1994-03-16 2004-05-15 Sankyo Co Okulares hypotonikum
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5510495A (en) * 1994-09-19 1996-04-23 The Du Pont Merck Pharmaceutical Company Process for the isolation and purification of ester functionalized imidazole intermediates by selective hydrolysis
DK0782996T3 (da) * 1994-09-20 1999-09-20 Wakunaga Seiyaku Kk Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
IT1292437B1 (it) * 1997-06-30 1999-02-08 Zambon Spa Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti
IT1295405B1 (it) * 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ES2154191B1 (es) * 1998-11-24 2001-10-16 Ferrer Int Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
GR20000100281A (el) * 2000-08-17 2002-05-24 Ιωαννης Ματσουκας Ανταγωνιστες του υποδοχεα της αγγεοτενσινης ιι και συνθετικες μεθοδοι για την θεραπεια της υπερτασης και καρδιοαγγειακων ασθενειων
WO2002096883A1 (en) 2001-05-31 2002-12-05 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
ATE398121T1 (de) 2003-01-16 2008-07-15 Teva Pharma Neue synthese von irbesartan
KR20060129393A (ko) 2004-01-20 2006-12-15 아이치 프레펙츄러 HLA-A2402-제한 Ep-CAM 특이적 CTL에인식되는 에피토프/펩티드 및 그 용도
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
EP1784398A1 (en) * 2004-09-02 2007-05-16 Teva Pharmaceutical Industries Ltd Purification of olmesartan medoxomil
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
EP1874302A4 (en) * 2005-04-20 2009-12-16 Merck & Co Inc ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
WO2008027385A2 (en) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Processes for the synthesis of 5-phenyl -1 trityl-1h-tetrazole
WO2008043996A2 (en) * 2006-10-09 2008-04-17 Cipla Limited Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil
AU2006351517B8 (en) * 2006-12-06 2012-01-19 Shenzhen Salubris Pharmaceuticals Co., Ltd. The salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof
JP6106437B2 (ja) * 2010-01-07 2017-03-29 アルカーメス ファーマ アイルランド リミテッド 複素芳香族化合物のプロドラッグ
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN104610232B (zh) * 2013-11-01 2019-09-20 深圳信立泰药业股份有限公司 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物
JP2022542437A (ja) 2019-08-02 2022-10-03 ランティオペプ ベスローテン ヴェンノーツハップ 癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
WO1991000281A2 (en) * 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Fused-ring aryl substituted imidazoles
DK0479903T3 (da) * 1989-06-30 1996-03-18 Du Pont Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
GB8927277D0 (en) * 1989-12-01 1990-01-31 Glaxo Group Ltd Chemical compounds
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5137902A (en) * 1990-07-13 1992-08-11 E. I. Du Pont De Nemours And Company 4-alkylimidazole derivatives and anti-hypertensive use thereof
DK0573218T3 (da) * 1992-06-02 2001-06-18 Sankyo Co 4-carboxyimidazolderivater som angiotensin-II antagonister og deres terapeutiske anvendelse

Also Published As

Publication number Publication date
IL106553A0 (en) 1993-12-08
PL307309A1 (en) 1995-05-15
ZA935693B (en) 1995-02-06
SG47108A1 (en) 1998-03-20
AU4790393A (en) 1994-03-03
US5310929A (en) 1994-05-10
SK13195A3 (en) 1995-07-11
WO1994003435A1 (en) 1994-02-17
JPH08500103A (ja) 1996-01-09
CN1090275A (zh) 1994-08-03
FI950485A7 (fi) 1995-02-03
CA2141692C (en) 2006-05-30
MX9304787A (es) 1995-01-31
FI950485L (fi) 1995-02-03
EP0654027A1 (en) 1995-05-24
FI950485A0 (fi) 1995-02-03
JP2892838B2 (ja) 1999-05-17
BR9306911A (pt) 1998-12-08
AU688735B2 (en) 1998-03-19
NO950404D0 (no) 1995-02-03
HU9500349D0 (en) 1995-03-28
CA2141692A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
TW221978B (OSRAM)
DK0551248T3 (OSRAM)
TW239131B (OSRAM)
TW227627B (OSRAM)
TW255930B (OSRAM)
DK0571874T3 (OSRAM)
TW222700B (OSRAM)
DK0597323T3 (OSRAM)
IN181441B (OSRAM)
BR9202713C1 (OSRAM)
DK0559942T3 (OSRAM)
DE9209779U1 (OSRAM)
DE9207553U1 (OSRAM)
AU631518B2 (OSRAM)
AU632452B2 (OSRAM)
TW266270B (OSRAM)
BRPI9204323A2 (OSRAM)
IN185559B (OSRAM)
AU2098792A (OSRAM)
EP0563564A3 (OSRAM)
AU633796B1 (OSRAM)
CN3013644S (OSRAM)
CN3013087S (OSRAM)
CN3012489S (OSRAM)
CN3011936S (OSRAM)